Physicians should encourage pharmaceutical companies to make socially responsible funding decisions and take an active role in setting biomedical research priorities by advocating for fair and effective allocations of public and private biomedical R & D investments.
A Canadian physician reports there is systematic bias to the outcome of published research funded by the pharmaceutical industry and believes more steps need to be taken to improve the integrity of clinical research reports in the United States and Canada.
Physicians need to help surrogate decision makers to make treatment and end-of-life decisions for those with severe neurological damage by proving a realistic prognosis and maintain strong lines of communication.
Presymptomatic genetic testing for neurodegenerative diseases can help patients make effective treatment decisions, but the medical profession needs to ensure that the increasing use of the tests is done responsibly.
A centralized registry to provide information to consumers regarding the effectiveness of clinical trials is needed to help patients make informed decisions about treatment.